Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

Haematologica. 2013 Nov;98(11):e146-8. doi: 10.3324/haematol.2013.095372.
No abstract available

Keywords: B-cell precursor acute lymphoblastic leukemia; EBF1-PDGFRB; refractory; tyrosine kinase inhibitor.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Benzamides / therapeutic use*
  • Humans
  • Imatinib Mesylate
  • Male
  • Piperazines / therapeutic use*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor beta / genetics*
  • Receptor, Platelet-Derived Growth Factor beta / metabolism
  • Trans-Activators / genetics*
  • Trans-Activators / metabolism
  • Treatment Outcome

Substances

  • Benzamides
  • EBF1 protein, human
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Trans-Activators
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor beta